Akers Biosciences Signs Distribution Agreement for BreathScan OxiChek(TM)
THOROFARE, NJ -- (Marketwired) -- 06/27/16 -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR) (the “Company” or “Akers Bio”), a developer of rapid health information technologies, has signed its first distribution agreement for BreathScan OxiChek™ (“OxiChek”) with Aero-Med, a division of Cardinal Health, a Fortune 500 health care services organization.
Developed by Akers Bio as part of the Akers Wellness line, OxiChek is the first disposable breath test to rapidly determine levels of oxidative stress in the body by measuring the levels of certain abundant free radicals. Frequent use of OxiChek may help health practitioners to monitor and adjust their clients’ regimen of nutritional supplementation in order to manage oxidative stress -- an indicator of the overall health and wellbeing of a person. OxiChek works with BreathScan Lync™, the new Bluetooth-enabled reading device from Akers Wellness, to enable users to monitor oxidative stress via a mobile device.
Aero-Med is targeting the large specific markets in the United States of anti-aging, functional and integrative health and wellness treatment practitioners and has already placed orders for OxiChek. OxiChek will be initially represented by an Aero-Med sales team focusing on the six New England states both through direct sales and, in due course, through an e-commerce platform under development.
Akers Bio intends to appoint further partners for OxiChek with distribution capabilities within other target markets for OxiChek including chiropractors and multi-level marketing organizations.
“The US health practitioner market is the most diverse in the world,” said John J. Gormally, CEO of Akers Bio. “OxiChek targets many of these different potential user bases so we needed a distributor with the broadest reach and I can think of no organization better suited than Aero-Med, which has extensive access to our target markets. I have worked with Aero-Med in the past and have been highly impressed with their distribution capabilities,” continued Mr. Gormally.
Dan DelMastro, CEO of Aero-Med, added, “Aero-Med recognizes the enormous market potential for products within the health and wellness sector so we are delighted to be incorporating OxiChek into our sales offering. Having personally observed the positive customer reaction to OxiChek at conventions in recent months, I am optimistic that there is strong potential for this product.”
About Akers Biosciences, Inc.
Akers Biosciences develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company’s state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be found at www.akersbio.com. Follow us on Twitter @AkersBio.
Cautionary Statement Regarding Forward Looking Statements Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company’s expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words “anticipate,” “believe,” “estimate,” “upcoming,” “plan,” “target,” “intend” and “expect” and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company’s actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=3026507
For more information:
Akers Biosciences, Inc.
Raymond F. Akers, Jr., PhD
Co-founder and Chief Scientific Director
Tel. +1 856 848 8698
Taglich Brothers, Inc. (Investor Relations)
Chris Schreiber
Tel. +1 917 445 6207
Email: cs@taglichbrothers.com
Vigo Communications (Public Relations)
Ben Simons / Fiona Henson
Tel. +44 (0)20 7830 9700
Email: akers@vigocomms.com
